Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Other Non Operating Income (2016 - 2020)

Soleno Therapeutics (SLNO) has disclosed Other Non Operating Income for 7 consecutive years, with $1000.0 as the latest value for Q3 2020.

  • On a quarterly basis, Other Non Operating Income fell 96.55% to $1000.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $34000.0, a 79.01% decrease, with the full-year FY2023 number at $2.6 million, up 759.33% from a year prior.
  • Other Non Operating Income was $1000.0 for Q3 2020 at Soleno Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.1 million in Q1 2016 to a low of -$672000.0 in Q1 2017.
  • A 5-year average of $62131.4 and a median of $26000.0 in 2018 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 162.57% in 2017, then soared 480.0% in 2018.
  • Soleno Therapeutics' Other Non Operating Income stood at $384497.0 in 2016, then crashed by 98.7% to $5000.0 in 2017, then skyrocketed by 480.0% to $29000.0 in 2018, then decreased by 27.59% to $21000.0 in 2019, then plummeted by 95.24% to $1000.0 in 2020.
  • Per Business Quant, the three most recent readings for SLNO's Other Non Operating Income are $1000.0 (Q3 2020), $1000.0 (Q2 2020), and $11000.0 (Q1 2020).